Pharmaceuticals

Global Loqtorzi Market Report 2026–2035: Key Forecasts and Growth Areas

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the loqtorzi market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Loqtorzi Market in 2026, and what figure is it projected to hit by 2030?

Historical growth can be attributed to a rise in NPC diagnosis rates within endemic regions, developments in immunotherapy research, promising early outcomes from PD-1 blockade trials, an increase in oncology research funding, and the expansion of specialty cancer centers.

Anticipated growth over the forecast period stems from several factors, including a rise in global approvals for immunotherapy medications, increased investment dedicated to rare cancer treatments, broader availability of oncology biologics, expanding utilization of combination immunotherapies, and continuous innovation within immune modulation therapies. Significant trends identified for the upcoming forecast period encompass the increasing integration of PD-1 inhibitors in addressing rare cancers, a heightened focus on therapies for nasopharyngeal carcinoma, the enlargement of immuno-oncology development pipelines, an uptick in the deployment of immune checkpoint blockade treatments, and intensified global activity in clinical trials.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20148&type=smp

Which Drivers Are Affecting Market Participation In The Loqtorzi Market?

The increasing occurrence of nasopharyngeal carcinoma is projected to drive the expansion of the loqtorzi market in the future. This specific cancer, impacting the nasopharynx, has a strong association with Epstein-Barr virus infection, and timely detection is crucial for successful treatment results. The growing prevalence of nasopharyngeal carcinoma stems from various elements, including heightened exposure to the Epstein-Barr virus, inherited genetic susceptibilities, environmental influences like tobacco and alcohol consumption, and nutritional practices, especially the intake of salted and processed foods. Loqtorzi (toripalimab) assists nasopharyngeal carcinoma (NPC) patients by boosting the immune system’s capacity to target cancer cells by blocking the PD-1 pathway, thereby providing an innovative therapeutic choice for individuals with recurrent or metastatic NPC, used either alongside chemotherapy or as a sole treatment following disease progression. For example, as reported by Cancer Research UK, a UK-based registered charity, in October 2024, the incidence of head and neck cancer in the UK is anticipated to rise by 3% when comparing the periods 2023–2025 and 2038–2040. Consequently, the increased prevalence of nasopharyngeal carcinoma is fueling the expansion of the loqtorzi market.

What Segment Classifications Make Up The Loqtorzi Market?

The loqtorzi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (intravenous), Lyophilized Powder For Reconstitution

2) By Indication: Treatment Of Small Cell Lung Cancer (SCLC), Treatment Of Other Solid Tumors

3) By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions

Which Market Trends Are Opening Growth Opportunities In The Loqtorzi Market?

A significant trend in the Loqtorzi market centers on developing biosimilars to expand product portfolios and offer more cost-effective treatment options compared to biologic therapies. Biosimilars are biologic products that exhibit high similarity to an approved reference product, with no clinically meaningful distinctions in terms of safety or effectiveness. They offer an affordable alternative to expensive biologic drugs once the original product’s patent has expired. For instance, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched a biosimilar of Coherus BioSciences’ (CHRS) Loqtorzi (toripalimab) in India under the brand name Zytorvi. The drug is indicated for the treatment of adults suffering from recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), which is a rare form of cancer. Loqtorzi received FDA approval in October 2023 for the first-line treatment of RM-NPC when used in combination with cisplatin and gemcitabine, and also as a monotherapy for patients whose disease has progressed after platinum-based chemotherapy. It holds the distinction of being the only FDA-approved immuno-oncology drug for this specific indication.

Which Major Industry Participants Are Leading The Loqtorzi Market Growth?

Major companies operating in the loqtorzi market are Coherus BioSciences Inc., Shanghai Junshi Biosciences Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/loqtorzi-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Loqtorzi Market?

North America was the largest region in the loqtorzi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the loqtorzi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Loqtorzi Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20148&type=smp

Browse Through More Reports Similar to the Global Loqtorzi Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795